RHEUMATIC FEVER / RHEUMATIC HEART DISEASE - Philippine Health Insurance .
(LETTERHEAD OF THE HOSPITAL ) RHEUMATIC FEVER / RHEUMATIC HEART DISEASE Benzathine Injection Booklet Name: Birthday: / / Age/Sex: Address: Registry No.: Registry Date.: Classification: NBB Co-pay Referring Institution : DIAGNOSIS: Rheumatic Fever, Definite Rheumatic Heart Disease Date Diagnose: Procedure Done (if any): Date of procedure :
CHECK ASSESSMENT (Based on ICD Codes) Rheumatic Fever without mention of heart involvement ; Arthritis, acute or subacute 100 Acute rheumatic pericarditis 101.0 Acute rheumatic endocarditis; acute rheumatic valvulitis 101.1 Acute rheumatic myocarditis 101.2 Other Acute RHD; Acute rheumatic pancarditis 101.8 Acute RHD unspecified; Active rheumatic carditis; 101.9 Rheumatic chorea with heart involvement; chorea NOS with heart involvement 102.0 Rheumatic chorea without heart involvement; Rheumatic chorea NOS 102.9 Mitral stenosis; Rheumatic valve obstruction 105.0 Rheumatic mitral insufficiency / regurgitation 105.1 Mitral stenosis with insufficiency or incompetence 105.2 Other mitral valve disease; Mitral valve failure 105.8 Mitral valve disease unspecified; Chronic mitral valve Disease NOS 105.9 Rheumatic aortic stenosis; aortic valve disorder 106.0 Rheumatic aortic insufficiency; Aortic Regurgitation 106.1 Rheumatic aortic stenosis with aortic regurgitation 106.2 Other rheumatic aortic valve disease 106.8 Rheumatic aortic valve disease unspecified NOS 106.9 Tricuspid stenosis; Rheumatic tricuspid valve stenosis 107.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS 108.0 Disorders of both mitral and tricuspid valves 108.1 Disorders of both aortic and tricuspid valves 108.2 Combined disorders of aortic, tricuspid and mitral valves 108.3 Other multiple valve diseases 108.8 Multiple valve disease unspecified 108.0 Rheumatic myocarditis 109.0 Rheumatic diseases of the endocardium; Chronic rheumatic valvulitis/ endocarditis 109.1 Chronic rheumatic pericarditis; Rheumatic adherent pericardium; 109.2
Patient Stage Based on Echo Valvular Classification (ENCRICLE) Stage A B C D Definition At risk Echo Description Patient with risk factor for development of heart disease Progressive Patient with progressive VHD (mild-mod, asymptomatic) Asymptomatic Asymptomatic patient who have the criteria severe for severe VHD: C1 – asymptomatic patient with severe VHD whom the left/right ventricles remain compensated C2 - asymptomatic patient with severe VHD with decompensation of the left/right ventricles Symptomatic Patients who have developed symptoms as a severe result of VHD RECOMMENDATION FOR SECONDARY PROPHYLAXIS (Please check): IM BPN 1.2 M units ORAL PENICILLIN Dose: ORAL ERYTHROMYCIN Dose: Every 21 days Every 28 days Duration: age 18 years age 21 years age 40 years Reason: Reason: Compliance for IM BPN/year Every 21 days POOR ( 50%) 12 FAIR ( 50 – 80%) 13 – 14 GOOD ( 80%) 15 - 16 EXCELLENT ( 100%) 17 Every 28 days 7 8 – 10 11 – 12 13
YEAR (1) : DATE DUE SITE DATE GIVEN REMARKS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 TOTAL INJECTIONS: Compliance status: LATEST LABS: 2D Echo : Date: Results: LVEDd LVEF LVFS Echo Stage ASO: Date ESR: Date CRP: Date (Please see page 3) RECOMMENDATION:
YEAR (2) : DATE DUE SITE DATE GIVEN REMARKS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 TOTAL INJECTIONS: Compliance status: LATEST LABS: 2D Echo : Date: Results: LVEDd LVEF LVFS ASO: Date ESR: Date CRP: Date Echo Stage (Please see page 3) RECOMMENDATION:
YEAR (3) : DATE GIVEN SITE SIGNATURE REMARKS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 TOTAL INJECTIONS: Compliance status: LATEST LABS: 2D Echo : Date: Results: LVEDd LVEF LVFS ASO: Date ESR: Date CRP: Date Echo Stage (Please see page 3) RECOMMENDATION:
YEAR (4) : DATE GIVEN SITE SIGNATURE REMARKS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 TOTAL INJECTIONS: Compliance status: LATEST LABS: 2D Echo : Date: Results: LVEDd LVEF LVFS Echo Stage ASO: Date ESR: Date CRP: Date (Please see page 3) RECOMMENDATION:
YEAR (5) : DATE GIVEN SITE SIGNATURE REMARKS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 TOTAL INJECTIONS: Compliance status: LATEST LABS: 2D Echo : Date: Results: LVEDd LVEF LVFS ASO: Date ESR: Date CRP: Date Echo Stage (Please see page 3) RECOMMENDATION:
Mitral valve disease unspecified; Chronic mitral valve Disease Rheumatic NOS 105.9 Rheumatic aortic stenosis; aortic valve disorder 106.0 Rheumatic aortic insufficiency; Aortic Regurgitation 106.1 Rheumatic aortic stenosis with aortic regurgitation 106.2 Other rheumatic aortic valve disease 106.8 Rheumatic aortic valve disease unspecified NOS 106.9
Rheumatic fever and rheumatic heart disease 5 Determinants of the disease burden of rheumatic fever and rheumatic heart disease 7 References 8 3. Pathogenesis of rheumatic fever 13 Introduction 13 Streptococcal M-protein 14 Streptococcal superantigens 14 The role of the human host in the development of
be living with rheumatic heart disease, and ap-proximately 306,000 deaths from rheumatic heart disease occur annually.2 Secondary antibiotic prophylaxis is the corner - stone of management of rheumatic fever and rheumatic heart disease.3 Intramuscular penicil-lin G benzathine (also known as benzathine benzylpenicillin) has been found to be more ef-
Acute rheumatic fever is an illness caused by a reaction to a bacterial throat or skin infection with group A streptococcus. Specific parts of the body affected include the heart, joints, brain and skin. Permanent damage to heart valves can result and this is known as rheumatic heart disease. Recurrent episodes of ARF may
low-risk settings (i.e., those with a rheumatic fever rheumatic heart disease prevalence 1 per 1000 population per year) moderate- to high-risk populations 2. The diagnosis of possible rheumatic fever. This category of diagnosis allows for the situation when a giv
rheumatic heart disease in Ugandan schoolchildren. Circulation 2012;125:3127-32. 10. Eynas Khalid, Hamid El Banna, Rehab Mahmoud, Hanadi Hassan, Laila El Mahdi, Sulafa Ali.Clinical and echocardiographic features of 370 children with rheumatic heart disease seen in Khartoum. Sudan Med J 201
The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease Michael D Seckeler Tracey R Hoke Department of Pediatrics, Division of Cardiology, University of virginia, . Pathophysiology Even though ARF has been recognized as a disease entity for at least 150 years, a clear understanding of the pathophysi- .
present with severe disease due to late diagnosis Only a minority have access to surgery Valve replacement: costs 4-10 000 USD and not readily available Poor long term outcome after surgery Eynas Khalid, SulafaAli et al.Clinical and echocardiographicfeatures of 370 children with rheumatic heart disease seen in Khartoum.
The level of management responsible for developing strategic goals is: A. line B. supervisor C. functional D. senior . D. other organisations that do business with the 14 Where a stakeholder is identified as having high interest and low power, an organisation should: keep them satisfied monitor their interests and power C. manage them closely keep them informed 15. Highfield Aeet 12 .
